-

Bio-Rad to Report Third-Quarter 2021 Financial Results, Thursday, October 28, 2021

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the third quarter 2021 on Thursday, October 28, 2021, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.

To listen, call 844-200-6205 within the U.S. or 929-526-1599 outside the U.S., access code: 535686. You may also listen to the conference call live via webcast that is available on the “Investor Relations” section of our website under “Quarterly Results” at bio-rad.com. A replay of the webcast will be available for up to a year.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. Please visit bio-rad.com for further information.

Contacts

Investor Contact:
Bio-Rad Laboratories, Inc.
Edward Chung, Vice President, Investor Relations
510-724-7000
ir@bio-rad.com

Media Contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Manager, Corporate Communications
510-741-6063
tina_cuccia@bio-rad.com

Bio-Rad Laboratories, Inc.

NYSE:BIO

Release Versions

Contacts

Investor Contact:
Bio-Rad Laboratories, Inc.
Edward Chung, Vice President, Investor Relations
510-724-7000
ir@bio-rad.com

Media Contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Manager, Corporate Communications
510-741-6063
tina_cuccia@bio-rad.com

More News From Bio-Rad Laboratories, Inc.

Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2025 on Thursday, May 1, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:30 PM Pacific Time (5:30 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S....

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2024. Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, commented: “Bio-Rad demonstrated resilience and adaptability in 2024. While the biopharma headwinds dampened our Life Science segment results, our Clinical Diagnostics business...

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has entered into a binding offer to purchase all equity interests in Stilla Technologies (“Stilla”). The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quart...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.